Swedish Orphan Biovitrum

sobi.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

77

Active

8

Phase 3

19

Total enrollment

10,487

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Efanesoctocog alfa5
Pacritinib2
Physician's Choice medications1
Anakinra8
Pegcetacoplan3
ELOCTA2

Next readouts

  • 2025-12-10
  • 2026-07
  • 2026-10-05
  • 2026-11-17
  • 2026-12-30
  • 2027-03
  • 2028-12
  • 2029-08-15

Top conditions

  • Hemophilia A8
  • Still's Disease, Adult-Onset4
  • Hereditary Tyrosinemia, Type I4
  • Haemophilia B4
  • Hemophilia B3
  • Healthy Volunteers3
  • Macrophage Activation Syndrome3
  • Haemophilia A3

Frequently asked questions about Swedish Orphan Biovitrum

How many clinical trials does Swedish Orphan Biovitrum have on ClinicalTrials.gov?
Swedish Orphan Biovitrum is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
How many of Swedish Orphan Biovitrum's trials are in Phase 3?
19 of Swedish Orphan Biovitrum's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Swedish Orphan Biovitrum focus on?
Swedish Orphan Biovitrum's most-studied conditions on ClinicalTrials.gov are Hemophilia A, Still's Disease, Adult-Onset, Hereditary Tyrosinemia, Type I, Haemophilia B, Hemophilia B.
When are Swedish Orphan Biovitrum's next clinical trial readouts?
Swedish Orphan Biovitrum has 8 upcoming primary-completion readouts tracked here; the soonest is “A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)”, expected around 2025-12-10.